PURPOSE: Merkel cell carcinoma (MCC) is a relatively rare, potentially aggressive cutaneous malignancy. We examined the clinical and histologic features of primary MCC that may correlate with the probability of a positive sentinel lymph node (SLN). METHODS: Ninety-five patients with MCC who underwent SLN biopsy at the University of Michigan were identified. SLN biopsy was performed on 97 primary tumors, and an SLN was identified in 93 instances. These were reviewed for clinical and histologic features and associated SLN positivity. Univariate associations between these characteristics and a positive SLN were tested for by using either the χ(2) or the Fisher's exact test. A backward elimination algorithm was used to help create a best multiple variable model to explain a positive SLN. RESULTS: SLN positivity was significantly associated with the clinical size of the lesion, greatest horizontal histologic dimension, tumor thickness, mitotic rate, and histologic growth pattern. Two competing multivariate models were generated to predict a positive SLN. The histologic growth pattern was present in both models and combined with either tumor thickness or mitotic rate. CONCLUSION: Increasing clinical size, increasing tumor thickness, increasing mitotic rate, and infiltrative tumor growth pattern were significantly associated with a greater likelihood of a positive SLN. By using the growth pattern and tumor thickness model, no subgroup of patients was predicted to have a lower than 15% to 20% likelihood of a positive SLN. This suggests that all patients presenting with MCC without clinical evidence of regional lymph node disease should be considered for SLN biopsy.
PURPOSE:Merkel cell carcinoma (MCC) is a relatively rare, potentially aggressive cutaneous malignancy. We examined the clinical and histologic features of primary MCC that may correlate with the probability of a positive sentinel lymph node (SLN). METHODS: Ninety-five patients with MCC who underwent SLN biopsy at the University of Michigan were identified. SLN biopsy was performed on 97 primary tumors, and an SLN was identified in 93 instances. These were reviewed for clinical and histologic features and associated SLN positivity. Univariate associations between these characteristics and a positive SLN were tested for by using either the χ(2) or the Fisher's exact test. A backward elimination algorithm was used to help create a best multiple variable model to explain a positive SLN. RESULTS: SLN positivity was significantly associated with the clinical size of the lesion, greatest horizontal histologic dimension, tumor thickness, mitotic rate, and histologic growth pattern. Two competing multivariate models were generated to predict a positive SLN. The histologic growth pattern was present in both models and combined with either tumor thickness or mitotic rate. CONCLUSION: Increasing clinical size, increasing tumor thickness, increasing mitotic rate, and infiltrative tumor growth pattern were significantly associated with a greater likelihood of a positive SLN. By using the growth pattern and tumor thickness model, no subgroup of patients was predicted to have a lower than 15% to 20% likelihood of a positive SLN. This suggests that all patients presenting with MCC without clinical evidence of regional lymph node disease should be considered for SLN biopsy.
Authors: Khosrow Mehrany; Clark C Otley; Roger H Weenig; P Kim Phillips; Randall K Roenigk; Tri H Nguyen Journal: Dermatol Surg Date: 2002-02 Impact factor: 3.398
Authors: Vernon K Sondak; Jeremy M G Taylor; Michael S Sabel; Yue Wang; Lori Lowe; Amelia C Grover; Alfred E Chang; Alan M Yahanda; James Moon; Timothy M Johnson Journal: Ann Surg Oncol Date: 2004-03 Impact factor: 5.344
Authors: Christopher K Bichakjian; Lori Lowe; Christopher D Lao; Howard M Sandler; Carol R Bradford; Timothy M Johnson; Sandra L Wong Journal: Cancer Date: 2007-07-01 Impact factor: 6.860
Authors: Amod A Sarnaik; Jonathan S Zager; L Elizabeth Cox; Tatiana M Ochoa; Jane L Messina; Vernon K Sondak Journal: J Clin Oncol Date: 2009-11-23 Impact factor: 44.544
Authors: Tony Y Eng; Melisa G Boersma; Clifton D Fuller; Virginia Goytia; William E Jones; Melissa Joyner; Dominic D Nguyen Journal: Am J Clin Oncol Date: 2007-12 Impact factor: 2.339
Authors: A Bob; F Nielen; J Krediet; J Schmitter; D Freundt; D Terhorst; J Röwert-Huber; J Kanitakis; E Stockfleth; Ch Ulrich; M Weichenthal; F Egberts; B Lange-Asschenfeldt Journal: J Cancer Res Clin Oncol Date: 2017-06-21 Impact factor: 4.553
Authors: Kelly L Harms; Lorena Lazo de la Vega; Daniel H Hovelson; Samantha Rahrig; Andi K Cani; Chia-Jen Liu; Douglas R Fullen; Min Wang; Aleodor A Andea; Christopher K Bichakjian; Timothy M Johnson; Scott A Tomlins; Paul W Harms Journal: JAMA Dermatol Date: 2017-06-01 Impact factor: 10.282
Authors: Samuel A Henderson; Michael T Tetzlaff; Penvadee Pattanaprichakul; Patricia Fox; Carlos A Torres-Cabala; Roland L Bassett; Victor G Prieto; Hunter W Richards; Jonathan L Curry Journal: J Cutan Pathol Date: 2014-10-28 Impact factor: 1.587
Authors: Franz O Smith; Binglin Yue; Suroosh S Marzban; Brooke L Walls; Michael Carr; Ryan S Jackson; Christopher A Puleo; Tapan Padhya; C Wayne Cruse; Ricardo J Gonzalez; Amod A Sarnaik; Michael J Schell; Ronald C DeConti; Jane L Messina; Vernon K Sondak; Jonathan S Zager Journal: Cancer Date: 2015-06-02 Impact factor: 6.860
Authors: Jayasri G Iyer; Barry E Storer; Kelly G Paulson; Bianca Lemos; Jerri Linn Phillips; Christopher K Bichakjian; Nathalie Zeitouni; Jeffrey E Gershenwald; Vernon Sondak; Clark C Otley; Siegrid S Yu; Timothy M Johnson; Nanette J Liegeois; David Byrd; Arthur Sober; Paul Nghiem Journal: J Am Acad Dermatol Date: 2014-02-09 Impact factor: 11.527